| Autor: |
Stas, P., Gansemans, Y., Lasters, I. |
| Zdroj: |
Current Trends in Monoclonal Antibody Development & Manufacturing; 2010, p271-291, 21p |
| Abstrakt: |
Therapeutic antibodies have gradually become a major class of drugs for the treatment of human diseases. As the number of approved therapeutics increases, and even more drugs are in clinical trials, our insights on the specifics of this class of drugs grow significantly. One of the issues related to therapeutic antibodies is that they are to a variable extend immunogenic. Indeed, the formation of anti-drug antibodies (ADA) after repeated administration of the antibody drug, poses a risk that should be assessed during drug development, as it possibly compromises drug safety, pharmacokinetics and required the dosage regime. This paper describes the observed immunogenicity of selected therapeutic antibodies, the drivers of immunogenicity and strategies to assess immunogenicity throughout the development cycle. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
